A detailed history of Amundi transactions in Alector, Inc. stock. As of the latest transaction made, Amundi holds 31,790 shares of ALEC stock, worth $125,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,790
Previous 31,790 -0.0%
Holding current value
$125,252
Previous $144,000 2.78%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.19 - $6.23 $71,766 - $106,707
-17,128 Reduced 35.01%
31,790 $144,000
Q1 2024

May 15, 2024

BUY
$5.69 - $8.08 $172,293 - $244,662
30,280 Added 162.46%
48,918 $294,000
Q4 2023

Feb 14, 2024

SELL
$3.77 - $8.39 $90,800 - $202,073
-24,085 Reduced 56.37%
18,638 $148,000
Q3 2023

Nov 14, 2023

BUY
$5.2 - $8.77 $82,362 - $138,908
15,839 Added 58.92%
42,723 $276,000
Q2 2023

Aug 14, 2023

BUY
$5.86 - $7.93 $128,556 - $173,968
21,938 Added 443.55%
26,884 $161,000
Q3 2022

Nov 14, 2022

BUY
$8.19 - $13.2 $40,507 - $65,287
4,946 New
4,946 $46,000
Q2 2022

Aug 15, 2022

SELL
$7.65 - $14.24 $29,773 - $55,422
-3,892 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$21.65 - $39.49 $84,261 - $153,695
3,892 New
3,892 $89,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $325M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.